Figure 3.

Human exp-NK cells significantly inhibit luciferase-transfected OPM2 myeloma tumor growth in the NOD/scid/IL2Rγ^null-hu model. (A) Imaging of OPM2 tumors expressing luciferase illustrates the myeloma burden in mice receiving PBS (control) or a total dose of 160×10⁶ exp-NK cells (given by four intravenous injections 48 h apart). Day 0 = date of NK cell injection #1. IL2 (100 U) was given intraperitoneally twice weekly to support NK cell survival in vivo. Three representative mice from each group are shown. (B) The fold tumor volume relative to baseline values was significantly lower in the cohort of mice that received 160×10⁶ exp-NK cells than in either the control group or the group that received a lower NK cell dose (40×10⁶). Each symbol represents one mouse in the different groups at the days indicated and median values are noted for each data set (−).